Shukra Pharmaceuticals Reports Negative Financial Results for Q3 2024

Shukra Pharmaceuticals, a microcap company in the pharmaceuticals and drugs industry, recently announced its financial results for the quarter ending September 2024. The company's stock has been given a 'Strong Sell' call by MarketsMOJO.

According to the financial report, Shukra Pharma. has seen a negative performance in the quarter, with a score of -18 compared to -5 in the previous quarter. However, there are some positive aspects to the company's financials. The dividend per share (DPS) has been consistently increasing over the past five years, with the highest being Rs 0.25. This indicates that the company is distributing higher dividends from its profits.

On the other hand, there are some concerning factors in the financial report. The net sales for the half-yearly period have decreased by -80.49% year on year, indicating a negative trend in sales. Similarly, the profit after tax (PAT) has also decreased by -79.92% year on year, showing a negative trend in profits. The operating cash flow has also been consistently decreasing over the past three years, indicating a decline in cash revenues from business operations.

In addition, the operating profit (PBDIT) for the quarter is at its lowest in the past five quarters, and the profit before tax (PBT) has also been consistently decreasing. The company's non-operating income is also high, which is not a sustainable business model.

Overall, Shukra Pharmaceuticals' financial performance for the quarter ending September 2024 has been negative, with some concerning trends in sales, profits, and cash flow. Investors should carefully consider these factors before making any investment decisions.